June M. Brown

June M. Brown

Auto-generated profile, based on publicly available information

June M. Brown

Bacterial Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2004 in International Journal of Systematic and Evolutionary Microbiology
Verified
Journal Article
Open access
MSMark F. Schinsky
Mark F. Schinsky
RMRoger E. Morey
Roger E. Morey
ASArnold G. Steigerwalt
Arnold G. Steigerwalt
Michael P DouglasMichael P Douglas
Michael P Douglas
RWRebecca W. Wilson
Rebecca W. Wilson
JBJune M. Brown
June M. Brown
The Mycobacterium fortuitum third biovariant complex (sorbitol-negative and sorbitol-positive) contains unnamed taxa first characterized in 1991. These organisms can cause respiratory infections, a spectrum of soft tissue and skeletal infections, bacteraemia and disseminated disease. To evaluate this group of organisms, clinical reference isolates and the type strains of M. fortuitum third biovariant complex sorbitol-negative (n=21), M. fortuitum third biovariant complex sorbitol-positive (n=3), M. fortuitum (n=3), Mycobacterium peregrinum (pipemidic acid-susceptible) (n=1), Mycobacterium porcinum (n=1), Mycobacterium senegalense (n=2) and Mycobacterium septicum (n=1) were characterized by using conventional phenotypic (morphological, physiological and antimicrobial susceptibilities), chemotaxonomic (HPLC and cellular fatty acids) and genotypic [RFLP of the rRNA gene (ribotyping), PCR-RFLP of a 439 bp segment of the 65 kDa hsp gene (PCR restriction analysis) and 16S rRNA gene sequence] analysis, DNA G+C content and DNA–DNA relatedness analyses. The results of these studies indicated that the strains comprised M. porcinum (n=13), M. septicum (n=1) and four novel closely related genetic groups within the M. fortuitum third biovariant complex: Mycobacterium boenickei sp. nov. (n=6), Mycobacterium houstonense sp. nov. (n=2), Mycobacterium neworleansense sp. nov. (n=1) and Mycobacterium brisbanense sp. nov. (n=1), with type strains ATCC 49935T (=W5998T=DSM 44677T), ATCC 49403T (=W5198T=DSM 44676T) ATCC 49404T (=W6705T=DSM 44679T) and ATCC 49938T (=W6743T=DSM 44680T), respectively.

1 April 2006 in International Journal of Systematic and Evolutionary Microbiology
Verified
Journal Article
Open access
PDF file
JBJune M. Brown
June M. Brown
ASArnold G. Steigerwalt
Arnold G. Steigerwalt
RMRoger E. Morey
Roger E. Morey
MDMaryam I. Daneshvar
Maryam I. Daneshvar
LRLeslie-Joy Romero
Leslie-Joy Romero
MMMichael M. McNeil
Michael M. McNeil
Taxonomic studies were performed on 13 clinical isolates (ten of which were epidemiologically related) that had been previously identified asOerskovia turbata. Comparative phylogenetic analysis, based on 16S rRNA gene sequences, indicated that the isolates are closely related toCellulosimicrobium cellulanswith sequence similarity values ranging from 99·5 to 99·8 %. Chemotaxonomic results (fatty acid profiles and menaquinones) supported the inclusion of these isolates in the genusCellulosimicrobium. The DNA G+C content was 74·5 mol%. The results of DNA–DNA reassociation, whole-cell sugars (with galactose as the characteristic whole sugar) and phenotypic properties, including antimicrobial resistance, indicated that these isolates are representatives of a novel species of the genusCellulosimicrobium. The nameCellulosimicrobium funkeisp. nov. is proposed for the novel strains, with strain W6122T(=ATCC BAA-886T=DSM 16025T=CCUG 50705T) as the type strain. The definition of this novelCellulosimicrobiumspecies will assist in the understanding of the epidemiology and clinical significance of these micro-organisms.

1 April 2005 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
JBJune M. Brown
June M. Brown
RFRodrick P. Frazier
Rodrick P. Frazier
RMRoger E. Morey
Roger E. Morey
ASArnold G. Steigerwalt
Arnold G. Steigerwalt
GPGerald J. Pellegrini
Gerald J. Pellegrini
MMMichael M. McNeil
Michael M. McNeil
CDC coryneform group A-3 bacteria are rare human pathogens. In this study, six group A-3 isolates (two from blood, one from cerebrospinal fluid, and one each from homograft valve, lip wound, and pilonidal cyst) were compared to the type strains of phenotypically related organisms, Cellulomonas fimi , Cellulomonas hominis , Oerskovia turbata , and Sanguibacter suarezii , and characterized by phenotypic, chemotaxonomic, and genotypic studies. DNA-DNA reassociation analysis identified two genomic groups, and phylogenetic analysis of the 16S rRNA gene sequence identified the taxonomic positions of these groups to genus level. Two groups were defined, and both were more closely related to Cellulomonas species: one group of three strains, for which we propose the new species Cellulomonas denverensis sp. nov., with the type strain W6929 (ATCC BAA-788 T or DSM 15764 T ), was related to C. hominis ATCC 51964 T (98.5% 16S rRNA gene sequence similarity), and the second group of three strains was related to C. hominis ATCC 51964 T (99.8 to 99.9% 16S rRNA gene sequence similarity). The definition of this new Cellulomonas species and the confirmation of three strains as C. hominis serve to further clarify the complex taxonomy of CDC coryneform group A-3 bacteria and will assist in our understanding of the epidemiology and clinical significance of these microorganisms.

1 August 2004 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
JBJune M. Brown
June M. Brown
KPKim N. Pham
Kim N. Pham
MMMichael M. McNeil
Michael M. McNeil
BLBrent A. Lasker
Brent A. Lasker
Nocardia farcinica is the most clinically significant species within the Nocardia asteroides complex. Differentiation of N. farcinica from other members of N. asteroides complex is important because this species characteristically demonstrates resistance to several extended-spectrum antimicrobial agents. Traditional phenotypic characterization of this species is time- and labor-intensive and often leads to misidentification in the clinical microbiology laboratory. We previously observed a 409-bp product for all strains of N. farcinica by using randomly amplified polymorphic DNA analysis with the primer DKU49. In this investigation, the 409-bp fragment was sequenced and then used to design a specific primer pair, Nf1 (16-mer) and Nf2 (16-mer), complementary to the 409-bp fragment. PCR amplification of genomic DNA from 28 N. farcinica isolates with Nf1 and Nf2 generated a single intense 314-bp fragment. The specificity of the assay with these primers was verified, since there were no PCR amplification products observed from heterologous nocardial species ( n = 59) or other related bacterial genera ( n = 41). Restriction enzyme digestion using CfoI and direct sequencing of the 314-bp fragment further confirmed the specificity of the assay for N. farcinica . This highly sensitive and specific PCR assay provides a rapid (within 1 day of obtaining DNA) method for identification of this medically important emerging pathogen. Rapid diagnosis of N. farcinica infection may allow for earlier initiation of effective therapy, thus improving patient outcome.

1 June 2004 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
MMMichael M. McNeil
Michael M. McNeil
JBJune M. Brown
June M. Brown
MCMichelle E. Carvalho
Michelle E. Carvalho
DHDannie G. Hollis
Dannie G. Hollis
RMRoger E. Morey
Roger E. Morey
LRL. Barth Reller
L. Barth Reller
Oerskovia turbata is an unusual bacterial cause of endocarditis and septicemia in immunocompromised patients. In this study, we compared 12 isolates from a 1975 medical center cluster, 11 originally identified as O. turbata (four from the blood of a homograft aortic valve-associated endocarditis patient and seven from contaminated homograft valves) and one CDC group A-3 strain from the blood of a second endocarditis patient with fatal outcome, with eight control strains from unrelated locations. The control strains included type and reference strains of O. turbata , Cellulomonas hominis , and CDC group A-3. The four blood isolates from the first patient and six of the valve isolates shared identical biochemical, antimicrobial susceptibility, and BglI ribotype patterns that differed from the second patient's isolate and control strains. The blood isolate from the second patient and the remaining valve isolate shared a phenotypic and genotypic profile and were phenotypically identical to, but epidemiologically different from, the CDC group A-3 reference strain with the strain-specific enzyme. Also, these isolates differed from the type strain and the other reference strains of C. hominis and O. turbata . Our results indicate that the four blood isolates from the first patient and six of the homograft valve isolates represent a single clone of O. turbata associated with endocarditis. Additionally, our results indicate that the blood isolate from the second patient and one of the homograft valve isolates differ from O. turbata and C. hominis and represent a unique clone of CDC group A-3 associated with fatal endocarditis.

3 September 2011 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
HNH. Niwa
H. Niwa
BLB. A. Lasker
B. A. Lasker
HHH. P. Hinrikson
H. P. Hinrikson
CFC. G. Franzen
C. G. Franzen
ASA. G. Steigerwalt
A. G. Steigerwalt
JBJ. M. Brown
J. M. Brown